Jinyuan EP (000546) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
10 Feb, 2026Executive summary
Revenue rose 59.05% year-over-year to ¥4.19 billion, driven by strong growth in environmental business income and new energy materials expansion.
Net loss attributable to shareholders was ¥49.60 million, down from a profit of ¥173.83 million in the prior year, mainly due to higher raw material costs and compressed margins.
Adjusted net loss (excluding non-recurring items) was ¥143.46 million, reflecting a further decline in core profitability.
Cash flow from operations improved significantly, with a net outflow of ¥87.82 million versus ¥492.83 million last year, up 82.18% year-over-year.
Financial highlights
Gross margin in the environmental segment declined by 5.37 percentage points year-over-year to -3.11%.
Basic and diluted EPS were both -¥0.0638, compared to ¥0.23 last year.
Total assets at period-end were ¥5.66 billion, up 0.53% from year-end 2024.
Net assets attributable to shareholders decreased 1.21% to ¥4.11 billion.
Significant government subsidies received, totaling ¥113.98 million, mainly benefiting the Jiangxi subsidiary.
Outlook and guidance
Focus remains on ramping up production at the Xizang Bachen Co. lithium project and optimizing environmental business operations.
The company will continue to divest underperforming assets and enhance resource management efficiency.
Strategic expansion in overseas lithium resources, with ongoing evaluation of projects in Argentina and Africa.
Latest events from Jinyuan EP
- Revenue up 187% and net profit returns positive, driven by resource utilization growth.000546
Q2 202410 Feb 2026 - Revenue and net profit soared year-over-year, led by waste resource utilization growth.000546
Q3 202410 Feb 2026 - Revenue up 136.8% and net profit positive, led by resource utilization growth.000546
Q4 202410 Feb 2026 - Revenue soared but net profit and cash flow declined amid margin pressure and ownership change.000546
Q1 202510 Feb 2026 - Revenue up 50% year-over-year, but net loss deepened due to higher costs and impairments.000546
Q3 202510 Feb 2026